ClinicalTrials.gg
CompletedNCT02446717Updated Sep 15, 2017Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

A Phase 2/3 interventional study of ABT-493, ABT-530 and ribavirin (RBV) in Chronic Hepatitis C, Hepatitis C Virus and HCV, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Hepatitis C, Chronic by AbbVie — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · AbbVie.

Enrollment
30th of 58
141 · median 144
Started
2015
with 24 others
Phase 2/3
5 of 83
none open now
Registered
34th of 83
by date

Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 30th largest by enrollment of the 58 interventional ones that give a count, is one of 25 that started in 2015, is one of 5 in phase 2/3, and was the 34th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies in Hepatitis C, Chronic by AbbVie is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies in Hepatitis C, Chronic by AbbVie as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.

03

Conditions studied

  • Chronic Hepatitis C
  • Hepatitis C Virus
  • HCV
  • Direct-Acting Antiviral Agent (DAA)-Experienced

Keywords

  • Hepatitis C
  • HCV Genotype 6
  • HCV GT1
  • Interferon (IFN) free
  • HCV Genotype 5
  • HCV
  • HCV GT4
  • HCV Genotype 4
  • Chronic Hepatitis C
  • Chronic HCV
  • Hepatitis C Genotype 1
  • HCV GT5
  • HCV Genotype 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients from 18 to 70 years in Arms A, B, and C; patients 18 years of age or older in Arms D and E.
  2. Previous treatment with DAA-containing regimen for chronic virus (HCV) infection resulting in either on-treatment virologic failure or post-treatment relapse
  3. Chronic HCV genotype (GT) 1, 4, 5, or 6-infection (GT4-6 in Arms D and E)

Exclusion criteria

Exclusion Criteria:

  1. History of severe, life-threatening or other significant sensitivity to any drug
  2. Female who is pregnant, planning to become pregnant during the study or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study
  3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol
  4. Positive for surface antigen (HBsAg) or anti- antibody (HIV Ab)
  5. Co-infection with more than one genotype
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Arm A

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.

    Drug: ABT-493, ABT-530

  • Experimental
    Arm B

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.

    Drug: ABT-493, ABT-530 · Drug: ribavirin (RBV)

  • Experimental
    Arm C

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.

    Drug: ABT-493, ABT-530

  • Experimental
    Arm D

    ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.

    Drug: ABT-493/ABT-530

  • Experimental
    Arm E

    ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.

    Drug: ABT-493/ABT-530

Interventions

  • DrugABT-493, ABT-530

    Drug pages: Glecaprevir · Pibrentasvir

    ABT-493 (tablet) dosed with ABT-530 (tablet)

    Also known as: ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, ABT-493/ABT-530 (ABT-493 coformulated with ABT-267) also known as MAVYRET

  • Tablet

  • DrugABT-493/ABT-530

    Drug page: Glecaprevir and pibrentasvir

    Tablet; ABT-493 coformulated with ABT-530

    Also known as: ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)

    SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 4 weeks after the last dose of study drug.

    Time frame: 4 weeks after the last actual dose of study drug

  2. Percentage of Participants With On-treatment Virologic Failure

    On-treatment virologic failure was defined as confirmed HCV RNA ≥ 100 IU after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.

    Time frame: Day 3, Treatment Weeks 1, 2, 4, 6, 8, 10, 12 (end of treatment for 12-week treatment arms), and 16 (end of treatment for 16-week treatment arm) or premature discontinuation from treatment

  3. Percentage of Participants With Post-treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants with HCV RNA levels \< LLOQ at the end of treatment, excluding reinfection.

    Time frame: From the end of treatment through 12 weeks after the last dose of study drug

07

Results

Posted Sep 15, 2017

Participant flow

Participant flow — Overall Study
MilestoneARM AARM BARM CARM DARM E
Started622224447
Completed621204346
Not completed01211
Withdrew: Adverse event00100
Withdrew: Lost to follow-up01101
Withdrew: Withdrew consent00010

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
percentage of participantsARM AARM BARM CARM DARM E
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)100 (61.0 to 100.0)95.5 (78.2 to 99.2)86.4 (66.7 to 95.3)88.6 (76.0 to 95.0)91.5 (80.1 to 96.6)
SecondaryPercentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)

SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 4 weeks after the last dose of study drug.

Time frame:
4 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)
percentage of participantsARM AARM BARM CARM DARM E
Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)100.0 (61.0 to 100.0)95.5 (78.2 to 99.2)95.5 (78.2 to 99.2)90.9 (78.8 to 96.4)91.5 (80.1 to 96.6)
SecondaryPercentage of Participants With On-treatment Virologic Failure

On-treatment virologic failure was defined as confirmed HCV RNA ≥ 100 IU after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.

Time frame:
Day 3, Treatment Weeks 1, 2, 4, 6, 8, 10, 12 (end of treatment for 12-week treatment arms), and 16 (end of treatment for 16-week treatment arm) or premature discontinuation from treatment
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participantsARM AARM BARM CARM DARM E
Percentage of Participants With On-treatment Virologic Failure0.0 (0.0 to 39.0)0.0 (0.0 to 14.9)4.5 (0.8 to 21.8)2.3 (0.4 to 11.8)8.5 (3.4 to 19.9)
SecondaryPercentage of Participants With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants with HCV RNA levels \< LLOQ at the end of treatment, excluding reinfection.

Time frame:
From the end of treatment through 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participantsARM AARM BARM CARM DARM E
Percentage of Participants With Post-treatment Relapse0.0 (0.0 to 39.0)4.8 (0.8 to 22.7)0.0 (0.0 to 15.5)9.3 (3.7 to 21.6)0.0 (0.0 to 8.2)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 20 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARM A—1/6 (16.7%)4/6 (66.7%)
ARM B—1/22 (4.5%)17/22 (77.3%)
ARM C—0/22 (0%)16/22 (72.7%)
ARM D—1/44 (2.3%)23/44 (52.3%)
ARM E—2/47 (4.3%)27/47 (57.4%)
Most frequent serious events
Most frequent serious events
EventARM AARM BARM CARM DARM E
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/220/220/440/47
FEMUR FRACTUREInjury, poisoning and procedural complications0/61/220/220/440/47
GASTROINTESTINAL VIRAL INFECTIONInfections and infestations0/60/220/221/440/47
WOUND INFECTIONInfections and infestations0/60/220/220/441/47
BACK PAINMusculoskeletal and connective tissue disorders0/60/220/220/441/47
Most frequent other events
Showing 10 of 27
Most frequent other events
EventARM AARM BARM CARM DARM E
FATIGUEGeneral disorders1/68/224/223/445/47
HEADACHENervous system disorders1/65/228/226/4411/47
NAUSEAGastrointestinal disorders1/66/223/224/443/47
INSOMNIAPsychiatric disorders0/66/220/222/442/47
ARTHRALGIAMusculoskeletal and connective tissue disorders0/60/224/221/442/47
DRY EYEEye disorders1/60/220/220/440/47
CONSTIPATIONGastrointestinal disorders1/62/221/220/444/47
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders1/62/221/220/441/47
HYPONATRAEMIAMetabolism and nutrition disorders1/60/220/220/440/47
MUSCULOSKELETAL STIFFNESSMusculoskeletal and connective tissue disorders1/60/220/220/440/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)ARM AARM BARM CARM DARM ETotal
Mean53.5 ± 9.1655.2 ± 6.2958.5 ± 6.5655.6 ± 8.5755.6 ± 8.3155.9 ± 7.88
Sex: Female, Male
Sex: Female, Male(Participants)ARM AARM BARM CARM DARM ETotal
Female324131436
Male320183133105
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10. Erratum In: Hepatology. 2017 Nov;66(5):1708. doi: 10.1002/hep.29551. PubMed 28128852 ↗
  • Brown A, Welzel TM, Conway B, Negro F, Brau N, Grebely J, Puoti M, Aghemo A, Kleine H, Pugatch D, Mensa FJ, Chen YJ, Lei Y, Lawitz E, Asselah T. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. Liver Int. 2020 Apr;40(4):778-786. doi: 10.1111/liv.14266. Epub 2019 Oct 18. PubMed 31568620 ↗
  • Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat. 2019 Aug;26(8):951-960. doi: 10.1111/jvh.13110. Epub 2019 May 20. PubMed 30977945 ↗
  • Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Worns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis. 2019 Oct 30;69(10):1657-1664. doi: 10.1093/cid/ciz022. PubMed 30923816 ↗
  • Flamm S, Reddy KR, Zadeikis N, Hassanein T, Bacon BR, Maieron A, Zeuzem S, Bourliere M, Calleja JL, Kosloski MP, Oberoi RK, Lin CW, Yu Y, Lovell S, Semizarov D, Mensa FJ. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10. PubMed 30012435 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Dec 2016, 20 months.

Results were first posted in Sep 2017, 9 months after primary completion. A results delay was requested in Jan 2017.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 18, 2015
StartActual
Apr 2015
Primary completionActual
Dec 2016
CompletionActual
Jan 2017
Results delay requested
Jan 31, 2017
Results first posted
Sep 15, 2017
Last update
Sep 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02446717
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Apr 2015
Primary completion
Dec 2016
Completion
Jan 2017
Results posted
Sep 15, 2017
Last update
Sep 15, 2017

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glecaprevir · Pibrentasvir · Ribavirin · Glecaprevir and pibrentasvir

Start the discussion